RxDoctor Payments Data

William Maguire, MD

Internal Medicine · Charleston, SCNPI 1528061397

Payments from drug & device makers

$6,351in general payments, 2019–2025

Across 339 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$566
  • Lilly USA, LLC$563
  • AbbVie$425
  • Pfizer$379
  • Novo Nordisk$363
  • Exact Sciences$338
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$6,25198%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,351 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$188,606
Medicare patients
424
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$147,762
JardianceEmpagliflozin118$131,775
EliquisApixaban124$124,509
JanuviaSitagliptin Phosphate90$88,886
TrulicityDulaglutide31$36,268
XareltoRivaroxaban27$23,147
LinzessLinaclotide32$20,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,027
RybelsusSemaglutide16$17,899
MyrbetriqMirabegron29$17,264
TradjentaLinagliptin22$14,022
FarxigaDapagliflozin Propanediol11$12,763
Lantus SolostarInsulin Glargine,hum.Rec.Anlog89$10,716
Levemir FlexpenInsulin Detemir34$9,748
EntrestoSacubitril/Valsartan11$9,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$363$165,660147 claims
Boehringer IngelheimJardiance, Tradjenta$169$145,796140 claims
PfizerEliquis, Paxlovid$379$127,368146 claims
MerckJanuvia$92$88,88690 claims
Lilly USA, LLCTrulicity$563$36,26831 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$319$32,78360 claims
Johnson & JohnsonXarelto$109$23,14727 claims
AstraZenecaFarxiga, Symbicort, Crestor$119$21,44339 claims
AbbVieLinzess$425$20,98932 claims
Astellas Pharma US IncMyrbetriq$223$17,26429 claims
NovartisEntresto$111$9,21711 claims
Collegium Pharmaceutical, Inc.Xtampza Er$13$5,88611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →